PDS Biotechnology Corp 8-K

What Happened

• On January 28, 2026, PDS Biotechnology Corporation (PDSB) issued a press release (filed as Exhibit 99.1 in its Form 8-K) announcing that results of a National Cancer Institute‑led study of its investigational Interleukin‑12 (IL‑12) tumor‑targeted immunocytokine, PDS01ADC, were presented at the American Association for Cancer Research (AACR) special conference on prostate cancer research held in Boston, MA on January 20–22, 2026.

Key Details

• Filing date: January 28, 2026 (Form 8-K, Item 8.01 — Other Events).
• Conference: AACR special conference on prostate cancer research, Boston, MA, January 20–22, 2026.
• Investigational agent: PDS01ADC, an IL‑12 tumor‑targeted immunocytokine.
• Study leadership: Results came from a study led by the National Cancer Institute; press release attached as Exhibit 99.1.

Why It Matters

• Presentation of NCI‑led study results at a high‑profile scientific meeting like AACR can raise the program’s visibility and provides independent scientific disclosure about PDS01ADC. For investors, this is a clinical‑development milestone rather than a financial or regulatory filing; review the full press release for any data details and watch for follow‑up clinical, regulatory, or corporate updates that could affect the company’s pipeline valuation.